The patient with cardiovascular disease: Treatment strategies for preventing major events
Version of Record online: 18 AUG 2009
Copyright © 2006 Wiley Periodicals, Inc.
Supplement: Preventing Cardiovascular Events in High-Risk Patients: Primary Care on the Front Line
Volume 29, Issue Supplement S2, pages 4–12, October 2006
How to Cite
Cuffe, M. (2006), The patient with cardiovascular disease: Treatment strategies for preventing major events. Clin Cardiol, 29: 4–12. doi: 10.1002/clc.4960291403
- Issue online: 18 AUG 2009
- Version of Record online: 18 AUG 2009
- Wyeth Laboratories, Philadelphia, Pennsylvania
- Cerebrio, New York, N.Y.
- University of Michigan Health Systems, Ann Arbor, Mich.
- cardiovascular events;
- pharmacologic therapy;
- clinical guidelines
An abundance of clinical data exists to support the ability of pharmacologic interventions to reduce risk for vascular events significantly; however, there remains a gap between this evidence and current clinical practice. Recent data from large-scale, placebo-controlled statin trials demonstrate that these agents dramatically reduce risk for cardiovascular events, even in moderate-risk patients with normal to moderately elevated cholesterol levels. Data from trials of a broad range of antihypertensives reinforce the value of blood pressure (BP) management and indicate that some of these agents may have additional benefits beyond BP reduction. Similarly, meta-analyses of randomized trials confirm that antiplatelet therapy prevents serious cardiovascular events in a wide range of high-risk patients. Each of these interventions alone has been demonstrated to reduce the risk for vascular events by approximately 25 to 30%. A combination approach utilizing intensive risk-reducing therapy with more than one of these agents has the potential to reduce the risk for vascular events by as much as 75%. Combined with nonpharmacologic risk reduction strategies, including exercise, diet, and smoking cessation, an opportunity exists to reduce the incidence of both first and recurrent cardiovascular events dramatically.